Alembic Pharmaceuticals Gains USFDA Tentative Approval for Darolutamide Tablets
Alembic Pharmaceuticals receives USFDA approval for Darolutamide Tablets, 300 mg
Business Standard
Image: Business Standard
Alembic Pharmaceuticals has received tentative approval from the US Food & Drug Administration (USFDA) for its Darolutamide Tablets, 300 mg. This drug is equivalent to Bayer HealthCare's Nubeqa Tablets and is indicated for treating various forms of prostate cancer.
- 01Alembic Pharmaceuticals received USFDA tentative approval for Darolutamide Tablets, 300 mg.
- 02The drug is therapeutically equivalent to Bayer's Nubeqa Tablets.
- 03Darolutamide is used to treat non-metastatic and metastatic prostate cancer.
- 04The approval is part of Alembic's strategy to expand its oncology portfolio.
- 05This marks a significant milestone for Alembic in the competitive oncology market.
Advertisement
In-Article Ad
Alembic Pharmaceuticals has announced that it has received tentative approval from the US Food & Drug Administration (USFDA) for its Darolutamide Tablets, 300 mg. This approval is for the Abbreviated New Drug Application (ANDA) and indicates that the drug is therapeutically equivalent to Bayer HealthCare Pharmaceuticals Inc.'s Nubeqa Tablets, 300 mg. Darolutamide functions as an androgen receptor inhibitor and is indicated for the treatment of adult patients with non-metastatic castration-resistant prostate cancer (nmCRPC), metastatic castration-sensitive prostate cancer (mCSPC), and mCSPC in combination with docetaxel. This approval is a significant step for Alembic as it aims to enhance its oncology product offerings in a competitive market.
Advertisement
In-Article Ad
Advertisement
In-Article Ad
More about Alembic Pharmaceuticals
Read the original article
Visit the source for the complete story.